恶性脑胶质瘤术后替莫唑胺化疗联合适形放疗的疗效观察

Clinical observation of temozlomide with three dimensional conformal radiotherapy in treatment of postoperative malignant glioma

目的:观察替莫唑胺联合适形放疗治疗恶性脑胶质瘤术后病例的临床疗效。方法:30例恶性脑胶质瘤术后的患者,13例行替莫唑胺联合适形放射治疗(治疗组),另17例单纯适形放射治疗(对照组)。结果:治疗组与对照组的中位生存时期为16.5个月和12.7个月;其1?2年生存率分别为76.9%?46.2%和52.9%?17.6%(P>0.05)。结论:替莫唑胺联合适形放射治疗恶性脑胶质瘤术后有提高生存率的趋势,并发症少。

Objective ：To evaluate the treatment efficacy of temozolomide（TMZ） with three dimensional conformal radiotherapy （3DCRT） for postoperative malignant glioma. Methods： Thirty postoperative patients with malignant glioma were randomized into two groups ：13 patients received TMZ and 3 DCRT （therapy group） ;17 patients received 3DCRT alone （control group）. Results： Median time to progression was 16.5 months in therapy group and 12.7 months in control group. The 1 - and 2 - year survival rates were 76.9% ,46.2% and 52.9% , 17.6% （ P 〉 0.05 ）. Conclusion： TMZ and 3DCRT for postoperative malignant glioma can improve the survival rate and decrease complications.